23 February 2017 (FDA News Release)-The US Food and Drug Administration (FDA) today allowed marketing of the PhenoTest BC Kit, performed on the Pheno System. This is the first test to identify organisms that cause bloodstream infections and provide information about which antibiotics the organism is likely to respond to. The test also reduces the amount of time it takes to provide this important information, which can guide antibiotic treatment recommendations more quickly.
Unlike traditional identification and antibiotic susceptibility tests that may take 24 to 48 hours after detection in a positive blood culture to provide test results, the PhenoTest BC Kit can identify bacteria or yeast from a positive blood culture in approximately 1.5 hours. For certain organisms, the test also provides important information to guide treatment recommendations in approximately 6.5 hours after the organisms are detected in blood cultures.
The test can identify 14 different species of bacteria and 2 species of yeast that cause bloodstream infections, while also providing antibiotic sensitivity information on 18 selected antibiotics for a subset of the identified organisms as appropriate. The test will also identify the presence of 2 indicators of antibiotic resistance, which can occur when potentially harmful bacteria change in a way that reduces or eliminates the effectiveness of antibiotics.
The PhenoTest BC Kit works by measuring the similarity of the infection-causing organism's genetic material to DNA known to be unique to specific bacteria or yeast. Once the organism is identified, it is mixed with antibiotics and the growth of the bacteria is measured by time-lapse images. If the organism does not grow when the antibiotic is present, this means that an antibiotic can possibly be used for treatment.
The FDA reviewed the data for the PhenoTest BC Kit through the de novo premarket review pathway, a regulatory pathway for devices of a new type with low-to-moderate risk that are not substantially equivalent to an already legally marketed device and for which special controls can be developed, in addition to general controls, to provide a reasonable assurance of safety and effectiveness of the devices. The FDA's decision to allow marketing was based largely on its review of the sponsor's primary clinical study of 1850 positive blood cultures. In this study, the PhenoTest BC Kit provided correct identification of the bacteria or yeast in the positive blood culture more than 95% of the time. Results for testing whether the bacteria were sensitive to antibiotics were also accurate when compared to traditional tests.
Risks associated with use of the PhenoTest BC Kit include false-positive findings. Results obtained from the test should always be interpreted alongside additional laboratory test results.
The PhenoTest BC Kit and the Pheno System are manufactured by Accelerate Diagnostics Inc in Tucson, Arizona.
Merck Drug Prevents Serious Infection After Marrow Transplant: Study
24 February 2017 (Reuters [Bill Berkrot])-An experimental Merck & Co drug succeeded in preventing clinically serious cytomegalovirus (CMV) following bone marrow transplant and was associated with a lower death rate compared with placebo in a late-stage study, the company said.
Merck said it will apply for US and European approval of the antiviral drug letermovir this year. It has been granted orphan status, which comes with several extra years of marketing exclusivity if approved.
In the study of 495 patients aged 18 and older who underwent bone marrow transplants, 37.5% who received either oral or intravenous letermovir developed clinically significant CMV infections by 24 weeks after the procedure. That compared with 60.6% of those who received a placebo, a statistically significant difference.
Letermovir was also associated with significantly lower all-cause mortality through week 24, with a death rate of just under 10% versus 16% in the placebo group, researchers reported.
"To me this is huge, " Dr Francisco Marty, the study's lead investigator from Dana-Farber Cancer Institute in Boston, said in a telephone interview.
The trial shows that a primary prophylaxis strategy works "with a drug that has a side effect profile better than anything we've had before and that may confer a survival advantage, " said Marty, who will present the data at a medical meeting in Orlando.
Data on how patients fared 48 weeks after transplant will be presented at a later date, Marty said.
While there are treatments against CMV once it occurs, prior attempts to find a safe drug that could prevent serious infection after marrow transplants have failed, most recently Chimerix's brincidofovir due to toxicity issues.
Adverse side effects more common with letermovir than placebo included vomiting, cough, and peripheral edema, researchers reported. The Merck drug did not adversely impact blood count or cause kidney damage seen with other drugs, Marty said.
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Cempra's Bacterial Skin Infection Drug Succeeds in Key Study
24 February 2017 (Reuters [Natalie Grover])-Cempra Inc said that its oral experimental drug to treat acute bacterial skin infections met the main goal of a late-stage study.
The drug, fusidic acid, was found as effective as the oral linezolid, in patients with serious acute bacterial skin and skin structure infections (ABSSSIs), Cempra said. These infections involve deep tissue or are associated with an underlying disease such as diabetes, and tend to be caused by serious gram-positive bacteria. ABSSSI leads to hospitalization of about 5.2 million patients in the United States and Western Europe each year and is often treated with intravenous therapies.
Cempra said only 6 of the patients given fusidic acid in the 716-patient study had serious side effects, compared with 8 patients treated with linezolid.
Cempra said it plans to meet with the US Food and Drug Administration to chart a path for the drug's approval.
Editorial comment. Fusidic acid is an old antibiotic and has been widely available outside the United States since the 1960s, where it is used orally, parenterally, and topically. It acts by inhibiting bacterial protein synthesis. It is bacteriostatic and has activity primarily against gram-positive organisms.
Fusidic acid exhibits no cross-resistance with other classes, because of its unique chemical structure. Its major use has been for Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus (MRSA) infections. It has relatively poor activity against streptococci and has no clinical usefulness against enterococci. It is well absorbed orally. Because resistance can emerge rapidly in vitro on exposure to fusidic acid alone, parenteral fusidic acid has usually been used in combination with agents such as vancomycin or rifampin in the treatment of systemic S. aureus infections to prevent emergence of resistance on therapy. It has been used as topical monotherapy for the treatment of superficial cutaneous infections and with rifampin or trimethoprim-sulfamethoxazole to clear MRSA colonization. The high fusidic acid local skin concentrations obtained with topical therapy may explain its efficacy for superficial cutaneous streptococcal infections. It is experimental only in the sense that it has never been approved for use in the United States.
Yemen Launches Polio Vaccination Drive Amid Fears Disease Could Reappear
21 February 2017 (Reuters [Emma Batha])-Yemen has launched a major polio vaccination campaign amid fears the disease could reappear in the warravaged nation where the health system is on the verge of collapse and aid agencies are warning of famine.
The World Health Organization (WHO), which is supporting the drive, said some 40 000 health workers aimed to immunize more than 5 million children under the age of 5 across the country.
Polio remains endemic in only 3 countries-Afghanistan, Pakistan, and Nigeria.
Yemen was declared polio-free in 2009, but experts say conflict-affected countries are particularly at risk of outbreaks because of disruption to their health systems.
WHO's spokesman on polio eradication, Sona Bari, said both Syria and Iraq saw polio outbreaks a few years ago.
"We have been very lucky that polio hasn't shown up in Yemen, but it is a virus that travels very easily and is very good at finding unprotected children. "
The immunization drive had been scheduled for last September, but lack of security has hampered access.
The vaccination teams will also target high-risk groups including families uprooted from their homes by fighting and refugees who have fled to Yemen from conflicts in Africa.
Around 2 million people are displaced in Yemen where nearly 2 years of civil war has pitted the Iran-allied Houthi group against a Western-backed Arab coalition led by Saudi Arabia.
The United Nations children's agency UNICEF, which is also helping with the vaccinations, warned of looming famine in Yemen where nearly half a million children have severe acute malnutrition.
Bari said there was a risk that polio vaccines would not be effective in malnourished children suffering from diarrhea because they would be flushed out.
She said WHO was also worried about the risks of polio emerging in countries in the Lake Chad basin, Syria, Iraq, Somalia, and South Sudan.
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